

澳大利亚生物技术协会 澳大利亚医疗技术公司名录



公司介绍

公司名称: Cellmid Limited

主要联系人姓名: Joseph Haklani

主要联系人职务: 业务发展经理

公司网址: www.cellmid.com.au

公司地址: Suite 1802, Level 18, 15 Castlereagh Street, Sydney NSW 2000

此公司已上市

公司简介

Cellmid 有限公司是一家澳大利亚生物技术公司。公司针对多种病征——特别是实体瘤，研发具有创新性的、一流的诊断测试和治疗方法。

Cellmid 拥有与中期因子（MK）相关最为广大齐全的专利组合。此专利组合对使用 MK 作为生物标志物和治疗靶点提供了专利保护。

作为生物标志物的 MK 有着广泛应用，既可单独使用也可结合其他生物标志共同使用。Cellmid 开发并销售唯一经过验证、拥有 CE 标志、符合 GMP 规章生产的血液中 MK 含量测试技术（MK-ELISA 试剂盒）。Cellmid 并授权其它多个公司（美国 Quest Diagnostics、新西兰 Pacific Edge、日本 Fujikura-Kasai）在内部的癌症诊断测试中使用 MK 作为生物标志。其中用来探测和监控膀胱癌复发的 Cxbladder 测试（属于 Pacific Edge 公司）已获得监管部门批准在美国、西班牙、澳大利亚和新西兰上市销售。Cellmid 持续不断在癌症和炎症性疾病领域寻求合作和授权 MK 的机会。

MK 是一种多功能生长因子，在胚胎发育期间表现特别明显，而在健康的成人體內则几乎不可见。超过 100 项已发表的研究证实了 MK 在多种病症，如缺血症、炎症、自身免疫失调，以及最引人注意的超过 25 种癌症中有惊人的过度表现。在活体切片检查中，患病的组织能检测出 MK，而健康的组织则无。更重要的是，作为一种可溶性细胞因子，升高的 MK 含量在血液和其他体液——如尿液、脑脊髓液中相当容易观察。这种特性使得 MK 可作为一方便、易得、非侵入性和费用低廉的生物标志物，并适用于人群疾病筛检和早期疾病检测。

Cellmid 同时正在研发针对 MK 的抗体疗法（人类化单株抗体）以治疗癌症和肾脏炎症类疾病。这些项目已处于后期临床前阶段。这些疗法以 MK 作为其中一种生物标志物，使用 Cellmid 公司的 MK-ELISA 进行测试。

关键技术或领先技术

中期因子作为癌症生物标志物项目

作为一新型、带有诊断性的生物标志物，中期因子（MK）有改善癌症在每个阶段治疗方式的潜力。中期因子在健康的成人體內几乎检测不到，但在超过 25 种癌症中有显著的过度表现情形，并使多种重大的肿瘤症状更加严重。研究表明 MK 测试可以用于改善多种癌症的早期检测、病情评估和预后评估，并可敏锐监测治疗后的疾病复发。

中期因子作为癌症生物标志物的效用已被广泛验证，与其他许多目前用来治疗疾病的生物标志物相比，中期因子有以下四点显著优势：

- 中期因子是一种存在于血液循环、尿液、体液中的分泌性蛋白，因此不再必须使用侵入性且痛苦的组织活检。
- 通常在疾病的早期（癌症 0 和 1 期），就可以检测到血液中中期因子含量升高。
- 中期因子可以用来诊断多种癌症——尤其是恶性肿瘤，并且表现优于许多常用的癌症标志物。
- 血液中的中期因子含量与预后评估相关，但不受病情（TNM，癌症分期）评分影响。

Cellmid 开发并销售 MK ELISA——夹心酶联免疫吸附测定以检测血清中的中期因子含量，此项测定完全符合 GMP 规章并拥有 CE 认证。

Cellmid 的 MK 检测技术方便整合到其他诊断平台中，并且可以与其他生物标志物一并使用。初步研究表明将 MK 与多种其他生物标志物联合使用能提高诊断的敏锐度和准确性，并降低假阳性和假阴性的比率。

类别

诊断类：肿瘤诊断

关键技术或领先技术的发展阶段

产品已上市

合作机会

Cellmid 正积极寻求贸易伙伴、合作者和 / 或有意购买许可的买家以进一步推动癌症标志物中期因子的商业发展。Cellmid 持有的多项专利覆盖了全球主要地区（包括中国），这些专利为使用中期因子做癌症检测、诊断、预后评估和监测提供了保护。使用 MK 作为生物标志物的机会包括：

- 作为单一或多种疾病的指征
 - 可于特定区域范围内或全球使用
 - 于 Cellmid 的 MK-ELISA 或其他平台上使用
 - 单独使用 MK 或联合其他生物标志物一起使用
-

Directory of Australian medtech companies



COMPANY DETAILS

Company name: Cellmid Limited

Key contact name: Joseph Haklani

Job title of key contact: Business Development Manager

Company website address: www.cellmid.com.au

Company address: Suite 1802, Level 18, 15 Castlereagh Street, Sydney NSW 2000

The company is Listed.

ABOUT THE COMPANY

Cellmid Limited is an Australian biotechnology company developing innovative first-in-class diagnostic tests and therapies for a number of disease indications, in particular solid tumours.

Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the growth factor midkine (MK), including patent protection globally for use of midkine as a biomarker and as a therapeutic target.

As a biomarker, MK has wide utility, either on its own or in combination with other biomarkers. Cellmid has developed and sells the only validated, CE-marked, GMP manufactured test for measuring blood MK levels (the MK-ELISA kit). Cellmid has also out-licensed MK as a biomarker to several other companies (Quest Diagnostics, USA; Pacific Edge, New Zealand; Fujikura-Kasai, Japan) for use in their own cancer diagnostic tests. One of these tests, Cxbladder (Pacific Edge), for detection and monitoring of recurrence in bladder cancer has received regulatory approval and is on the market in the US, Spain, Australia, and New Zealand. Cellmid continues to seek opportunities to collaborate with and/or out-license MK in the cancer and inflammatory diseases space.

Midkine is a pleiotropic growth factor prominently expressed during embryogenesis but down-regulated to near absent levels in healthy adults. Over 100 published studies have demonstrated striking MK overexpression in various pathologies, including ischemia, inflammation, autoimmunity and, most notably, in more than 25 different cancers. Midkine is detectable in biopsies of diseased, but not healthy, tissues. Significantly, because it is a soluble cytokine, elevated MK is readily apparent in the blood and other body fluids such as urine and cerebrospinal fluid, making MK a convenient, accessible, non-invasive and inexpensive biomarker for population screening and early disease detection.

Cellmid is also developing MK-specific antibody therapies (humanised monoclonals) for treating cancer and inflammatory kidney diseases. These programs are in late preclinical stage. Midkine functions as the companion biomarker to these therapeutics, utilising Cellmid's MK-ELISA as the test.

KEY OR LEAD TECHNOLOGY

Midkine cancer biomarker program

A novel diagnostic biomarker, midkine (MK) has the potential to improve the way cancer is managed at all phases of the disease. Midkine is barely detectable in healthy adults but is found to be significantly expressed in over 25 cancer types, enhancing a variety of significant tumorigenic effects. Studies show that MK testing can improve early detection, staging and prognosis in a variety of cancers, as well as sensitively monitor disease recurrence after treatment.

Midkine has been extensively validated as a cancer biomarker and has four distinct advantages over many current biomarkers used to manage disease:

- Midkine is a secreted protein present in circulating blood, urine, and body fluids, eliminating the need for invasive and painful tissue biopsies
- Elevated blood midkine is often apparent very early in disease etiology (cancer stages 0 and 1)
- Midkine is a marker of a wide range of cancers, particularly carcinomas, that out-performs many of the commonly used generic cancer biomarkers.
- Blood midkine levels correlate with prognosis independent of disease (TNM) score .

Cellmid has developed and sells the MK ELISA, a fully validated GMP manufactured and CE-marked sandwich enzyme immunoassay for the detection of midkine in serum.

Cellmid's MK detection technology is readily adaptable to other diagnostic platforms and is amenable to multiplexing with other biomarkers. Pilot studies have demonstrated that multiplexing MK with various other biomarkers can improve test sensitivity and specificity and reduce false positive and negative rates.

Category

Diagnostics: Diagnostics oncology

Point of development of key or lead technology

Product on the market

OPPORTUNITIES SOUGHT

Cellmid is actively seeking partners, collaborators and/or licensees to further commercialise midkine as a cancer biomarker. Cellmid holds patents in key geographical regions (including China) globally covering the use of midkine for detection, diagnosis, prognosis and monitoring of cancer.

Opportunities to use MK as biomarker include:

- single or multiple disease indications
- specific territories or global
- Cellmid's MK-ELISA or other platforms

- use of MK alone or in combination with other biomarkers.